Clinical Trials Logo

Clinical Trial Summary

This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old. The purpose of this study is to find out whether a medicine called nintedanib helps people with progressive lung fibrosis. Participants are put into 2 groups randomly, which means by chance. 1 group gets nintedanib as capsules twice a day. The other group gets placebo as capsules twice a day. Placebo capsules look like nintedanib capsules but do not contain any medicine. Participants are in the study for about 1 year. During this time, they visit the study site about 10 times. At some visits, participants perform a lung function test. The doctors check whether study treatment can slow down the loss of lung function. The doctors also regularly check participants' health and take note of any unwanted effects.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05065190
Study type Interventional
Source Boehringer Ingelheim
Status Not yet recruiting
Phase Phase 3
Start date December 31, 2021
Completion date March 12, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04119115 - Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases
Recruiting NCT04559581 - Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan
Recruiting NCT02543073 - MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Phase 1/Phase 2
Completed NCT02251964 - Rituximab in Interstitial Pneumonitis Phase 2/Phase 3
Terminated NCT01432080 - Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant Phase 2
Completed NCT01442779 - Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04016168 - Idiopathic Pulmonary Fibrosis and Serum Bank
Not yet recruiting NCT04930666 - Development of BREATHE-ALD, a Shared Decision-Making Intervention for Adults With Advanced Lung Disease
Recruiting NCT00258583 - Dorothy P. and Richard P. Simmons Center for ILD Research Registry
Recruiting NCT04159129 - Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients
Active, not recruiting NCT03313180 - A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis. Phase 3
Completed NCT03136120 - Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease
Recruiting NCT04702893 - INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation
Completed NCT03099187 - A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease Phase 2
Recruiting NCT04707781 - Database for Interstitial Lung Disease
Recruiting NCT03596528 - Interstitial Lung Disease (ILD). Diagnostic Yield of Surgical Lung Biopsy Versus Cryobiopsy in the Same Surgical Stage. N/A
Not yet recruiting NCT03858842 - Non-interventional Study Describing Epidemiology, Prognosis and Patient Healthcare Costs in France, 2010-2017
Not yet recruiting NCT02705144 - Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis N/A
Completed NCT02370693 - Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Phase 2
Completed NCT01553981 - A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Phase 3